Effect of Weight Loss on Breast Density Using Digital Mammography and MRI in Women Who Are At Increased Risk For Breast Cancer



Status:Recruiting
Conditions:Healthy Studies
Therapuetic Areas:Other
Healthy:No
Age Range:30 - 50
Updated:3/16/2015
Start Date:February 2011
End Date:December 2016
Contact:Research Coordinator
Email:cancertrials@northwestern.edu
Phone:312-695-1301

Use our guide to learn which trials are right for you!

Effect of Weight Loss on Breast Density Using Both Digital Mammography and Breast MRI

Diagnostic procedures, such as digital mammography and MRI, may help measure how weight loss
affects breast density in women who are at increased risk for breast cancer.

OBJECTIVES: I. To determine if weight loss in patients undergoing Roux en Y gastric bypass
procedures has any effect on breast density as measured by mammography and breast MRI.
OUTLINE: GROUP I: Participants undergo mammography and MRI at baseline and 1 year.
Participants also undergo gastric bypass surgery. GROUP II: Participants undergo mammography
and MRI at baseline and 1 year. After completion of study treatment, patients are followed
up at 1 year.

Inclusion Criteria:

- Women eligible for gastric bypass surgery

- Pre-menopausal women

- All women will have signed an informed consent form prior to participating in study
procedures

Exclusion Criteria:

- Women with a history of breast cancer

- Women currently taking exogenous hormone replacement therapy

- Women currently taking a SERM

- Women currently taking an aromatase inhibitor

- Pregnant or lactating women

- Women who have been pregnant or lactating in the past 2 years

- Women who have metallic or other surgical implants

- All subjects will have a determination of their estimated glomerular filtration rate
(eGFR) within 24 hours of undergoing any study where gadolinium based contrast agents
will be administered

- Subjects should not have a known history of recent onset acute renal dysfunction

- Subjects with a history of stable chronic renal dysfunction may participate in
studies using GBCA based on their eGFR, as outlined below

- Subjects should not have severe liver dysfunction, particularly when associated with
kidney disease

- Subjects should receive GBCAs in the perioperative period (i.e. within 4 weeks) after
renal or liver transplantation
We found this trial at
1
site
201 East Huron Street
Chicago, Illinois 60611
(847) 491-3741
Northwestern University Northwestern is recognized both nationally and internationally for the quality of its educational...
?
mi
from
Chicago, IL
Click here to add this to my saved trials